{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T04:10:47Z","timestamp":1749096647693,"version":"3.41.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-025-23235-9","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T09:58:29Z","timestamp":1749031109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Human papillomavirus vaccine administration opportunities at well visits in adolescents"],"prefix":"10.1186","volume":"25","author":[{"given":"Kunal","family":"Saxena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneesha Fathima Syed","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"23235_CR1","unstructured":"Centers for Disease Control and Prevention (CDC). HPV and, Cancer. https:\/\/www.cdc.gov\/cancer\/hpv\/statistics\/cases.htm; 2023 [accessed 3 April 2024."},{"key":"23235_CR2","doi-asserted-by":"crossref","unstructured":"Villarroel MA, Galinsky AM, Lu PJ, Pingali C. Human Papillomavirus Vaccination Coverage in Children Ages 9\u201317 Years: United States, 2022. NCHS Data Brief 2024:(495).","DOI":"10.15620\/cdc:145593"},{"key":"23235_CR3","doi-asserted-by":"publisher","unstructured":"Adams DA, Thomas KR, Jajosky RA, Foster L, Baroi G, Sharp P, et al. Summary of notifiable infectious diseases and Conditions - United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;64:(53). https:\/\/doi.org\/10.15585\/mmwr.mm6453a1.","DOI":"10.15585\/mmwr.mm6453a1"},{"key":"23235_CR4","unstructured":"Advisory Committee on Immunization Practices (ACIP). Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger. https:\/\/www.cdc.gov\/vaccines\/schedules\/downloads\/child\/0-18yrs-child-combined-schedule.pdf; 2024 [accessed February 26, 2024."},{"key":"23235_CR5","unstructured":"American Academy of Pediatrics (AAP). Human Papillomavirus Vaccines. https:\/\/www.aap.org\/en\/patient-care\/immunizations\/human-papillomavirus-vaccines\/; 2024 [accessed March 1, 2024."},{"key":"23235_CR6","doi-asserted-by":"publisher","unstructured":"O\u2019Leary ST. Why the American academy of pediatrics recommends initiating HPV vaccine at age 9. Hum Vaccin Immunother. 2022;18(6). https:\/\/doi.org\/10.1080\/21645515.2022.2146434.","DOI":"10.1080\/21645515.2022.2146434"},{"key":"23235_CR7","doi-asserted-by":"publisher","unstructured":"Henley SJ, Singh SD, King J, Wilson RJ, O\u2019Neil ME, Ryerson AB. Invasive Cancer incidence and Survival - United States, 2013. MMWR Morb Mortal Wkly Rep. 2017;66:(3). https:\/\/doi.org\/10.15585\/mmwr.mm6603a1.","DOI":"10.15585\/mmwr.mm6603a1"},{"key":"23235_CR8","doi-asserted-by":"publisher","unstructured":"Pingali C, Yankey D, Chen M, Elam-Evans LD, Markowitz LE, DeSisto CL, et al. National vaccination coverage among adolescents aged 13\u201317 Years - National immunization Survey-Teen, united States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(33). https:\/\/doi.org\/10.15585\/mmwr.mm7333a1.","DOI":"10.15585\/mmwr.mm7333a1"},{"key":"23235_CR9","unstructured":"US Department of Health and Human Services. Healthy People. 2030: Increase the proportion of adolescents who get recommended doses of the HPV vaccine \u2014 IID\u201308. https:\/\/health.gov\/healthypeople\/objectives-and-data\/browse-objectives\/vaccination\/increase-proportion-adolescents-who-get-recommended-doses-hpv-vaccine-iid-08; 2024 [accessed February 28, 2024."},{"key":"23235_CR10","unstructured":"St Sauver JL, Rutten LJF, Ebbert JO, Jacobson DJ, McGree ME, Jacobson RM. Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion. Prev Med. 2016;8910.1016\/j.ypmed.2016.02.039."},{"key":"23235_CR11","doi-asserted-by":"publisher","unstructured":"Perkins RB, Humiston S, Oliver K. Evidence supporting the initiation of HPV vaccination starting at age 9: collection overview. Hum Vaccin Immunother. 2023;19:(3). https:\/\/doi.org\/10.1080\/21645515.2023.2269026.","DOI":"10.1080\/21645515.2023.2269026"},{"key":"23235_CR12","doi-asserted-by":"publisher","unstructured":"Minihan AK, Bandi P, Star J, Fisher-Borne M, Saslow D, Jemal A. The association of initiating HPV vaccination at ages 9\u201310 years and up-to-date status among adolescents ages 13\u201317 years, 2016\u20132020. Hum Vaccin Immunother. 2023;19(1). https:\/\/doi.org\/10.1080\/21645515.2023.2175555.","DOI":"10.1080\/21645515.2023.2175555"},{"key":"23235_CR13","doi-asserted-by":"publisher","unstructured":"Bednarczyk RA, Brandt HM. Descriptive epidemiology of age at HPV vaccination: analysis using the 2020 NIS-Teen. Hum Vaccin Immunother. 2023;19:(1). https:\/\/doi.org\/10.1080\/21645515.2023.2204784.","DOI":"10.1080\/21645515.2023.2204784"},{"key":"23235_CR14","doi-asserted-by":"publisher","unstructured":"Saxena K, Kathe N, Sardana P, Yao L, Chen YT, Brewer NT. HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US. Hum Vaccin Immunother. 2023;19(1). https:\/\/doi.org\/10.1080\/21645515.2022.2161253.","DOI":"10.1080\/21645515.2022.2161253"},{"key":"23235_CR15","doi-asserted-by":"crossref","unstructured":"Goodman E, Felsher M, Wang D, Yao L, Chen YT. Early initiation of HPV vaccination and series completion in early and Mid-Adolescence. Pediatrics. 2023;151(3). https:\/\/doi.org\/10.1542\/peds.2022\u2013058794.","DOI":"10.1542\/peds.2022-058794"},{"key":"23235_CR16","doi-asserted-by":"publisher","unstructured":"Coyne-Beasley T, Ortiz RR. Recommending HPV vaccination at age 9 to reduce health disparities: communication challenges and opportunities. Hum Vaccin Immunother. 2023;19:(1). https:\/\/doi.org\/10.1080\/21645515.2023.2178219.","DOI":"10.1080\/21645515.2023.2178219"},{"key":"23235_CR17","doi-asserted-by":"crossref","unstructured":"Biancarelli DL, Drainoni ML, Perkins RB. Provider Experience Recommending HPV Vaccination Before Age 11 Years. J Pediatr. 2020;21710.1016\/j.jpeds.2019.10.025.","DOI":"10.1016\/j.jpeds.2019.10.025"},{"key":"23235_CR18","doi-asserted-by":"publisher","unstructured":"Giuliano AR, Lazcano-Ponce E, Villa L, Nolan T, Marchant C, Radley D, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis. 2007;196:(8). https:\/\/doi.org\/10.1086\/521679.","DOI":"10.1086\/521679"},{"key":"23235_CR19","doi-asserted-by":"publisher","unstructured":"Cavazos-Rehg PA, Krauss MJ, Spitznagel EL, Schootman M, Bucholz KK, Peipert JF, et al. Age of sexual debut among US adolescents. Contraception. 2009;80(2). https:\/\/doi.org\/10.1016\/j.contraception.2009.02.014.","DOI":"10.1016\/j.contraception.2009.02.014"},{"key":"23235_CR20","doi-asserted-by":"publisher","unstructured":"Kelly MK, Grundmeier RW, Stephens-Shields AJ, Localio R, Shone LP, Wright M, et al. Missed opportunities for human papillomavirus vaccination at office visits during which influenza vaccine was administered: an AAP pediatric research in office settings (PROS) National primary care research network study. Vaccine. 2020;38(33). https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.090.","DOI":"10.1016\/j.vaccine.2020.05.090"},{"key":"23235_CR21","doi-asserted-by":"publisher","unstructured":"Henry KA, Swiecki-Sikora AL, Stroup AM, Warner EL, Kepka D. Area-based socioeconomic factors and human papillomavirus (HPV) vaccination among teen boys in the united States. BMC Public Health. 2017;18:(1). https:\/\/doi.org\/10.1186\/s12889-017-4567-2.","DOI":"10.1186\/s12889-017-4567-2"},{"key":"23235_CR22","doi-asserted-by":"publisher","unstructured":"Williams CL, Walker TY, Elam-Evans LD, Yankey D, Fredua B, Saraiya M, et al. Factors associated with not receiving HPV vaccine among adolescents by metropolitan statistical area status, united States, National immunization Survey-Teen, 2016\u20132017. Hum Vaccin Immunother. 2020;16(3). https:\/\/doi.org\/10.1080\/21645515.2019.1670036.","DOI":"10.1080\/21645515.2019.1670036"},{"key":"23235_CR23","doi-asserted-by":"crossref","unstructured":"Ryan GW, Perry SS, Scherer A, Charlton ME, Ashida S, Gilbert PA et al. Factors contributing to missed opportunities for human papillomavirus vaccination among adolescents, ages 11 to 13, in Iowa. Vaccine X. 2022;1110.1016\/j.jvacx.2022.100192.","DOI":"10.1016\/j.jvacx.2022.100192"},{"key":"23235_CR24","doi-asserted-by":"publisher","unstructured":"Newcomer SR, Freeman RE, Albers AN, Murgel S, Thaker J, Rechlin A, et al. Missed opportunities for human papillomavirus vaccine series initiation in a large, rural U.S. State. Hum Vaccin Immunother. 2022;18(1). https:\/\/doi.org\/10.1080\/21645515.2021.2016304.","DOI":"10.1080\/21645515.2021.2016304"},{"key":"23235_CR25","doi-asserted-by":"publisher","unstructured":"Zorn S, Darville-Sanders G, Vu T, Carter A, Treend K, Raunio C, et al. Multi-level quality improvement strategies to optimize HPV vaccination starting at the 9-year well child visit: success stories from two private pediatric clinics. Hum Vaccin Immunother. 2023;19(1). https:\/\/doi.org\/10.1080\/21645515.2022.2163807.","DOI":"10.1080\/21645515.2022.2163807"},{"key":"23235_CR26","first-page":"29","volume":"63","author":"S Stokley","year":"2014","unstructured":"Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, et al. Human papillomavirus vaccination coverage among adolescents, 2007\u20132013, and postlicensure vaccine safety monitoring, 2006\u20132014\u2013United States. MMWR Morb Mortal Wkly Rep. 2014;63:29.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"23235_CR27","doi-asserted-by":"crossref","unstructured":"Saxena K, Patterson-Lomba O, Gomez-Lievano A, Zion A, Cunningham-Erves J, Kepka D. Assessing the long-term implications of age 9 initiation of HPV vaccination on series completion by age 13\u201315 in the US: projections from an age-structured vaccination model. Front Pediatr. 2024;1210.3389\/fped.2024.1393897.","DOI":"10.3389\/fped.2024.1393897"},{"key":"23235_CR28","unstructured":"President\u2019s Cancer Panel. HPV Vaccination for Cancer Prevention: Progress, Opportunities, and a Renewed Call to Action. A Report to the President of the United States from the Chair of the President\u2019s Cancer Panel. Bethesda (MD) 2018;2018 November."},{"key":"23235_CR29","doi-asserted-by":"publisher","unstructured":"QuickStats. Percentage* of Children(dagger) aged\u2009<\u200918 years who received a Well-Child checkup in the past 12 Months,(section sign) by Age Group and Year - National Health Interview Survey, United States, 2008 and 2018(paragraph sign). MMWR Morb Mortal Wkly Rep. 2020;69(8). https:\/\/doi.org\/10.15585\/mmwr.mm6908a5.","DOI":"10.15585\/mmwr.mm6908a5"},{"key":"23235_CR30","doi-asserted-by":"crossref","unstructured":"Allison MA, Hurley LP, Markowitz L, Crane LA, Brtnikova M, Beaty BL, et al. Primary Care Physicians\u2019 Perspectives About HPV Vaccine. Pediatrics. 2016;137(2). https:\/\/doi.org\/10.1542\/peds.2015\u20132488.","DOI":"10.1542\/peds.2015-2488"},{"key":"23235_CR31","doi-asserted-by":"crossref","unstructured":"Perkins RB, Clark JA, Apte G, Vercruysse JL, Sumner JJ, Wall-Haas CL, et al. Missed opportunities for HPV vaccination in adolescent girls: a qualitative study. Pediatrics. 2014;134:(3). https:\/\/doi.org\/10.1542\/peds.2014\u20130442.","DOI":"10.1542\/peds.2014-0442"},{"key":"23235_CR32","doi-asserted-by":"publisher","unstructured":"Aragones A, Gany F, Kaplan A, Bruno D. An opportunity to increase human papillomavirus vaccination rates: change the guidelines. Hum Vaccin Immunother. 2022;18(6). https:\/\/doi.org\/10.1080\/21645515.2022.2136444.","DOI":"10.1080\/21645515.2022.2136444"},{"key":"23235_CR33","doi-asserted-by":"publisher","unstructured":"Kong WY, Huang Q, Thompson P, Grabert BK, Brewer NT, Gilkey MB. Recommending human papillomavirus vaccination at age 9: A National survey of primary care professionals. Acad Pediatr. 2022;22(4). https:\/\/doi.org\/10.1016\/j.acap.2022.01.008.","DOI":"10.1016\/j.acap.2022.01.008"},{"key":"23235_CR34","doi-asserted-by":"publisher","unstructured":"Kahn BZ, Reiter PL, Kritikos KI, Gilkey MB, Queen TL, Brewer NT. Framing of National HPV vaccine recommendations and willingness to recommend at ages 9\u201310. Hum Vaccin Immunother. 2023;19:(1). https:\/\/doi.org\/10.1080\/21645515.2023.2172276.","DOI":"10.1080\/21645515.2023.2172276"},{"key":"23235_CR35","doi-asserted-by":"publisher","unstructured":"Lu PJ, Yankey D, Fredua B, Hung MC, Walker TY, Markowitz LE, et al. National and State-Specific estimates of settings of receiving human papillomavirus vaccination among adolescents in the united States. J Adolesc Health. 2021;69:(4). https:\/\/doi.org\/10.1016\/j.jadohealth.2021.03.005.","DOI":"10.1016\/j.jadohealth.2021.03.005"},{"key":"23235_CR36","doi-asserted-by":"publisher","unstructured":"Kujawski SA, Yao L, Wang HE, Carias C, Chen YT. Impact of the COVID-19 pandemic on pediatric and adolescent vaccinations and well child visits in the united States: A database analysis. Vaccine. 2022;40:(5). https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.064.","DOI":"10.1016\/j.vaccine.2021.12.064"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-23235-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-23235-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-23235-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T09:58:33Z","timestamp":1749031113000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-23235-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23235"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-23235-9","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis used de-identified data from databases that comply with US privacy laws and regulations. No institutional review board approval or specific informed consent was required. The data that support the findings of this study are available from Merative MarketScan Commercial Claims and Encounters Database and the MarketScan Multi-State Medicaid Database, however, restrictions apply to the availability of these data, which were used under license for this study. Data are, however, available from the authors upon reasonable request and with permission of Merative MarketScan Commercial Claims and Encounters Database and the MarketScan Multi-State Medicaid Database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KS, LA, AM, DW, and YZ are current employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and may hold equity interest in Merck & Co., Inc., Rahway, NJ, USA. AFSM was an intern at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA at the time of the study. KO has no conflicts of interest to report.This study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2084"}}